Wired News – Merck and AstraZeneca Announced that EMA Will Review MAA for LYNPARZA(R) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer

LONDON, UK / ACCESSWIRE / April 05, 2018 / Active-Investors.com has just released a free research report on Merck & Co., Inc. (NYSE: MRK) (“Merck”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MRK as the Company’s latest news hit the wire. On April 03, 2018, Merck and AstraZeneca PLC (NYSE: AZN) announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for LYNPARZA® (olaparib) for use in patients with BRCA-mutated, HER2-negative metastatic breast cancer, previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Merck and AstraZeneca most recent news is on our radar and our team decided to put out fantastic reports on these companies that are now available for free below:

www.active-investors.com/registration-sg/?symbol=MRK

www.active-investors.com/registration-sg/?symbol=AZN

If approved, LYNPARZA® would be the first poly ADP-ribose polymerase (PARP) inhibitor to treat breast cancer patients in Europe.

The MAA is Based on Data from OlympiAD Trial

The MAA is based on data from the randomized, open-label, phase-3 OlympiAD trial, which investigated LYNPARZA® versus chemotherapy. 205 patients were randomized to receive LYNPARZA® and 97 patients were randomized to receive chemotherapy. Patients in the OlympiAD trial had germline BRCA-mutated, HER2-negative breast cancer, and received LYNPARZA® for treatment in the metastatic setting. In the trial, LYNPARZA® significantly prolonged progression-free survival compared to chemotherapy and reduced the risk of disease progression or death by 42%. Patients with measurable disease taking LYNPARZA® experienced an objective response rate of 52%, double the response rate for those in the chemotherapy arm, which was 23%.

FDA Approved LYNPARZA® in Germline BRCA-Mutated Metastatic Breast Cancer

On January 12, 2018, the US Food and Drug Administration (FDA) approved LYNPARZA® for use in patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor positive (HR+) breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. This approval makes LYNPARZA® the first and only PARP inhibitor approved in metastatic breast cancer.

What is Metastatic Breast Cancer?

Metastatic breast cancer is the most advanced stage of breast cancer that has spread beyond the breast to other organs in the body, most often bones, lungs, liver, or brain. Treatment options for metastatic breast cancer depend on several factors, including the spread area, the patient’s overall health, levels of hormone receptors, and HER2 in the tumor. HER2 is specialized proteins and is found on the surface of breast cells. About 15% to 20% of patients with invasive breast cancer have abnormally high levels of HER2. HER2-positive metastatic breast cancer spreads to the brain in up to half of patients.

About Lynparza®

Lynparza® (olaparib) is the first approved oral PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells. It is a prescription medicine used for maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, when the cancer has come back. Lynparza® is used after the cancer has responded to treatment with platinum-based chemotherapy. Lynparza® is a registered trademark of AstraZeneca. In July 2017, AstraZeneca and Merck collaborated to jointly co-develop and co-commercialize Lynparza®.

About Merck & Co., Inc.

Merck, known as MSD outside of the United States and Canada, is a leading global biopharmaceutical company that has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Headquartered in Kenilworth, New Jersey, the Company through its prescription medicines, vaccines, biologic therapies, and animal health products, works with customers and operate in more than 140 countries.

Stock Performance Snapshot

April 04, 2018 – At Wednesday’s closing bell, Merck’s stock marginally rose 0.83%, ending the trading session at $54.54.

Volume traded for the day: 8.89 million shares.

Stock performance in the last month – up 0.26%

After yesterday’s close, Merck’s market cap was at $148.72 billion.

Price to Earnings (P/E) ratio was at 29.97.

The stock has a dividend yield of 3.52%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers – Major industry. This sector was up 1.4% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 495211